{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:55:16Z","timestamp":1790801716360,"version":"4.1.0"},"reference-count":119,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NHMRC","award":["APP1157287"],"award-info":[{"award-number":["APP1157287"]}]},{"name":"Cystic Fibrosis Australia","award":["APP1157287"],"award-info":[{"award-number":["APP1157287"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Characterized by impaired mucus transport and subsequent enhanced colonization of bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic fibrosis (CF). Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus) are the two most common types of bacteria detected in CF lungs, which undergo multiple adaptational mechanisms such as biofilm formation resulting in chronic pulmonary infections. With the advantages of greater airway concentration and minimized systemic toxicity, inhaled antibiotics are introduced to treat chronic pulmonary infection in CF. Inhaled tobramycin, aztreonam, levofloxacin, and colistin are the four most common discussed inhaled antibiotics targeting P. aeruginosa. Additionally, inhaled liposomal amikacin and murepavadin are also in development. This review will discuss the virulence factors and adaptational mechanisms of P. aeruginosa and S. aureus in CF. The mechanism of action, efficacy and safety, current status, and indications of corresponding inhaled antibiotics will be summarized. Combination therapy and the strategies to select an optimal inhaled antibiotic protocol will also be discussed.<\/jats:p>","DOI":"10.3390\/antibiotics12030484","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:28:17Z","timestamp":1677637697000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis"],"prefix":"10.3390","volume":"12","author":[{"given":"Danni","family":"Li","sequence":"first","affiliation":[{"name":"Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-4824","authenticated-orcid":false,"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[{"name":"Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: An overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir. Care."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Anim. Model. Exp. Med."},{"key":"ref_3","unstructured":"Cystic Fibrosis Foundation (2022, December 05). Patient Registry, 2021 Annual Data Report. Available online: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: Current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_5","first-page":"100286","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1056\/NEJMc1907962","article-title":"Muco-obstructive lung diseases. Reply","volume":"381","author":"Boucher","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Harwood, K.H., McQuade, R.M., Jarnicki, A., and Schneider-Futschik, E.K. (2021). Anti-inflammatory influences of cystic fibrosis transmembrane conductance regulator drugs on lung inflammation in cystic fibrosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147606"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u201cunlikely\u201d pair: The antimicrobial synergy of polymyxin b in combination with the cystic fibrosis transmembrane conductance regulator drugs kalydeco and orkambi","volume":"2","author":"Schneider","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: Past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2014.12.007","article-title":"Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years","volume":"14","author":"Kidd","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17476348.2016.1177460","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis: Pathophysiological mechanisms and therapeutic approaches","volume":"10","author":"Turnbull","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Brian","year":"2009","journal-title":"Lancet"},{"key":"ref_13","unstructured":"Cystic Fibrosis Foundation (2022, November 16). Cystic Fibrosis Foundation Patient Registry. Available online: https:\/\/www.cff.org\/community-posts\/2018-06\/highlights-2017-cf-foundation-patient-registry."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jurado-Martin, I., Sainz-Mejias, M., and McClean, S. (2021). Pseudomonas aeruginosa: An audacious pathogen with an adaptable arsenal of virulence factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/acsinfecdis.7b00065","article-title":"Investigating the interaction of octapeptin a3 with model bacterial membranes","volume":"3","author":"Han","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.arcmed.2020.12.004","article-title":"Pseudomonas aeruginosa: Genetic adaptation, a strategy for its persistence in cystic fibrosis","volume":"52","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0966-842X(00)88974-X","article-title":"Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis","volume":"3","author":"Deretic","year":"1995","journal-title":"Trends Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1309\/KJRPC7DD5TR9NTDM","article-title":"Mucoid pseudomonas in cystic fibrosis","volume":"128","author":"Pritt","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_19","first-page":"91","article-title":"Microevolution of pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung","volume":"358","author":"Hogardt","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/AAC.06486-11","article-title":"In vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in pseudomonas aeruginosa biofilm infection","volume":"56","author":"Hengzhuang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/nass\/nrp026","article-title":"Multiple activities of c-di-gmp in pseudomonas aeruginosa","volume":"53","author":"Lory","year":"2009","journal-title":"Nucleic Acids Symp Ser."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.0602138103","article-title":"Genetic adaptation by pseudomonas aeruginosa to the airways of cystic fibrosis patients","volume":"103","author":"Smith","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/ppul.24139","article-title":"Biology and management of methicillin resistant staphylococcus aureus in cystic fibrosis","volume":"53","author":"Akil","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00077-20","DOI":"10.1128\/mSystems.00077-20","article-title":"The killing mechanism of teixobactin against methicillin-resistant staphylococcus aureus: An untargeted metabolomics study","volume":"5","author":"Hussein","year":"2020","journal-title":"mSystems"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of staphylococcus aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"To, K., Cao, R., Yegiazaryan, A., Owens, J., and Venketaraman, V. (2020). General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and mycobacterium abscessus. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082541"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","article-title":"Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens","volume":"15","author":"Cogen","year":"2018","journal-title":"Ann. Am. Thorac Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2217\/fmb-2021-0150","article-title":"Management of chronic pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis","volume":"16","author":"Elborn","year":"2021","journal-title":"Future Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciz364","article-title":"Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections","volume":"69","author":"Waters","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 36294, tobramycin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tobramycin."},{"key":"ref_32","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 5742832, azactam, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Azactam."},{"key":"ref_33","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 149096, levofloxacin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Levofloxacin."},{"key":"ref_34","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 5311054, colistin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Colistin."},{"key":"ref_35","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 37768, amikacin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Amikacin."},{"key":"ref_36","unstructured":"National Center for Biotechnology Information (2023, January 12). Pubchem Compound Summary for Cid 91824766, murepavadin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Murepavadin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: An overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ppul.21188","article-title":"The use of high resolution computerized tomography (hrct) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease","volume":"45","author":"Nasr","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00148581-200709001-00004","article-title":"A formulation of aerosolized tobramycin (bramitob) in the treatment of patients with cystic fibrosis and pseudomonas aeruginosa infection: A double-blind, placebo-controlled, multicenter study","volume":"9","author":"Chuchalin","year":"2007","journal-title":"Paediatr. Drugs."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with pseudomonas aeruginosa","volume":"9","author":"Lenoir","year":"2007","journal-title":"Paediatr. Drugs."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The eager trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for p. Aeruginosa infection in cystic fibrosis: The evolve trial","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.10074","article-title":"Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and pseudomonas aeruginosa infection","volume":"33","author":"Quittner","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (azli) in patients with cystic fibrosis, mild lung impairment, and p. Aeruginosa","volume":"10","author":"Wainwright","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. Inhaled tobramycin in cystic fibrosis: A comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (mp-376) in patients with cystic fibrosis with pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (apt-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Geller","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis","volume":"15","author":"Flume","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (colobreathe dpi) in patients with cystic fibrosis: A randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase ii studies of nebulised arikace in cf patients with pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","article-title":"Amikacin liposome inhalation suspension for chronic pseudomonas aeruginosa infection in cystic fibrosis","volume":"19","author":"Bilton","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_57","unstructured":"Spexis (2022, December 06). Inhaled Murepavadin. Available online: https:\/\/spexisbio.com\/pol7080\/."},{"key":"ref_58","unstructured":"U.S. Food and Drug Aministration (2022, December 20). Tobi (Tobramycin Inhalation Solution), for Oral Inhalation Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/050753s022lbl.pdf."},{"key":"ref_59","unstructured":"U.S. Food and Drug Administration (2022, December 20). Bethkis (Tobramycin Inhalation Solution), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/201820s000lbl.pdf."},{"key":"ref_60","unstructured":"U.S. Food and Drug Administration (2022, December 20). Tobi Podhaler (Tobramycin Inhalation Powder), for Oral Inhalation Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/201688s006lbl.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","article-title":"Management of pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin","volume":"10","author":"Ehsan","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"Beta-lactams and beta-lactamase inhibitors: An overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb Perspect Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1056\/NEJMc071717","article-title":"Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome","volume":"357","author":"McCoy","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_64","unstructured":"U.S. Food and Drug Administration (2022, December 20). Cayston (Aztreonam for Inhalation Solution), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050814s007lbl.pdf."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.32607\/20758251-2011-3-4-94-99","article-title":"Inhibition of DNA gyrase by levofloxacin and related fluorine-containing heterocyclic compounds","volume":"3","author":"Tunitskaya","year":"2011","journal-title":"Acta Nat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.00248-09","article-title":"In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis","volume":"54","author":"King","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (apt-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one f508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (apt-1026) treatment for cystic fibrosis and chronic pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_70","unstructured":"European Medicines Agency (2022, December 20). Quinsair\u2014Levofloxacin. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quinsair."},{"key":"ref_71","unstructured":"Canadian Agency for Drugs and Technologies in Health (2022, December 20). Cdr Clinical Reveiw Report for Quinsair. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/clinical\/SR0493_Quinsair_CL_Report.pdf."},{"key":"ref_72","unstructured":"Electronic Medicines Compendium (2022, December 20). Quinsair 240 mg Neubuliser Solution. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/7202\/smpc#gref."},{"key":"ref_73","unstructured":"U.S. Food and Drug Administration (2022, December 23). Fluoroquinolones Drug Safety Communication\u2014Safety Announcement, Available online: https:\/\/www.fda.gov\/media\/119532\/download."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/acsinfecdis.0c00108","article-title":"Effective strategy targeting polymyxin-resistant gram-negative pathogens: Polymyxin b in combination with the selective serotonin reuptake inhibitor sertraline","volume":"6","author":"Hussein","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acsptsci.0c00030","article-title":"Metabolomic description of ivacaftor elevating polymyxin b mediated antibacterial activity in cystic fibrosis pseudomonas aeruginosa","volume":"3","author":"Allobawi","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_77","first-page":"99","article-title":"Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: An evidence-based review of its place in therapy","volume":"9","author":"Ballmann","year":"2014","journal-title":"Core Evid."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcf.2006.05.009","article-title":"Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis","volume":"5","author":"Adeboyeku","year":"2006","journal-title":"J. Cyst. Fibros."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00365548.2010.509333","article-title":"Resistance to tobramycin and colistin in isolates of pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment","volume":"42","author":"Valenza","year":"2010","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/thorax.58.9.794","article-title":"Survey of resistance of pseudomonas aeruginosa from uk patients with cystic fibrosis to six commonly prescribed antimicrobial agents","volume":"58","author":"Pitt","year":"2003","journal-title":"Thorax"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/rmed.2000.0834","article-title":"A ten year review of colomycin","volume":"94","author":"Littlewood","year":"2000","journal-title":"Respir. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/26.2.247","article-title":"Rapid emergence of resistance in pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains","volume":"26","author":"Giwercman","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02013454","article-title":"Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin b","volume":"5","author":"Cohen","year":"1986","journal-title":"Eur. J. Clin. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.127.2.522","article-title":"Bronchial constriction and inhaled colistin in cystic fibrosis","volume":"127","author":"Alothman","year":"2005","journal-title":"Chest"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0954-6111(94)90028-0","article-title":"Nebulized colistin causes chest tightness in adults with cystic fibrosis","volume":"88","author":"Maddison","year":"1994","journal-title":"Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jcf.2020.08.001","article-title":"Long-term safety study of colistimethate sodium (colobreathe(r)): Findings from the uk cystic fibrosis registry","volume":"20","author":"Kaplan","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_88","unstructured":"Electronic Medicines Compendium (2022, December 20). Colomycin 1 Million International Units (iu) Powder for Solution for Injection, Infusion and Inhalation. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1094\/smpc#gref."},{"key":"ref_89","unstructured":"National Institute of Allergy and Infectious Diseases (2023, January 12). Aerosolized and Intravenous Colistin in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01863719."},{"key":"ref_90","unstructured":"Cystic Fibrosis Foundation (2022, December 01). Drug Development Pipeline\u2014Inhaled Colistin (Colifin). Available online: https:\/\/apps.cff.org\/Trials\/Pipeline\/details\/10196\/Inhaled-Colistin-ColiFin."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: A review in mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/AAC.02421-13","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies","volume":"58","author":"Okusanya","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jcf.2021.05.013","article-title":"Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic p. Aeruginosa infection","volume":"20","author":"Bilton","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_94","unstructured":"U.S. Food and Drug Administration (2022, December 20). Arikayce (Amikacin Liposome Inhalation Suspension), for Oral Inhalation Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/207356s004lbl.pdf."},{"key":"ref_95","unstructured":"Electronic Medicines Compendium (2022, December 20). Arikayce liposomal 590mg nebulise dispersion. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/12067\/smpc#gref."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"ofac465","DOI":"10.1093\/ofid\/ofac465","article-title":"Amikacin liposomal inhalation suspension in the treatment of mycobacterium abscessus lung infection: A french observational experience","volume":"9","author":"Chiron","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: A new antibiotic class in the pipeline","volume":"16","author":"Dale","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkaa529","article-title":"Murepavadin antimicrobial activity against and resistance development in cystic fibrosis pseudomonas aeruginosa isolates","volume":"76","author":"Morosini","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Bernardini, F., Dale, G.E., Wach, A., and Obrecht, D. (2019). Pharmacokinetics and pharmacodynamics of murepavadin (pol7080) in neutropenic lung infection models when evaluated by aerosol administration. J. Cyst. Fibros., 18.","DOI":"10.1016\/S1569-1993(19)30120-1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e01541-19","DOI":"10.1128\/AAC.01541-19","article-title":"Susceptibility of pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics","volume":"64","author":"Ekkelenkamp","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/jac\/dkab222","article-title":"Anti-biofilm activity of murepavadin against cystic fibrosis pseudomonas aeruginosa isolates","volume":"76","author":"Ekkelenkamp","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphar.2019.00849","article-title":"Antimicrobial treatment of staphylococcus aureus in patients with cystic fibrosis","volume":"10","author":"Esposito","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_103","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: A review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_104","unstructured":"National Center for Biotechnology Information (2023, January 13). Pubchem Compound Summary for Cid 446987, fosfomycin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Fosfomycin."},{"key":"ref_105","unstructured":"National Center for Biotechnology Information (2023, January 13). Pubchem Compound Summary for Cid 14969, vancomycin, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Vancomycin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ppul.10231","article-title":"Methicillin-resistant staphylococcus aureus in children with cystic fibrosis: An eradication protocol","volume":"36","author":"Solis","year":"2003","journal-title":"Pediatr. Pulmonol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ppul.23519","article-title":"Eradication of methicillin resistant staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study","volume":"51","author":"Kappler","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kiefer, A., Bogdan, C., and Melichar, V.O. (2018). Successful eradication of newly acquired mrsa in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0588-6"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1099-0496(199810)26:4<287::AID-PPUL9>3.0.CO;2-#","article-title":"Aerosolized vancomycin for the treatment of methicillin-resistant staphylococcus aureus infection in cystic fibrosis","volume":"26","author":"Maiz","year":"1998","journal-title":"Pediatr. Pulmonol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: Mechanism and resistance","volume":"7","author":"Silver","year":"2017","journal-title":"Cold Spring Harb Perspect Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.201401-034OI","article-title":"Is there a role for antimicrobial stewardship in cystic fibrosis?","volume":"11","year":"2014","journal-title":"Ann. Am. Thorac Soc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"Ecfs best practice guidelines: The 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.4.1.35","article-title":"Microbiology of airway disease in patients with cystic fibrosis","volume":"4","author":"Gilligan","year":"1991","journal-title":"Clin. Microbiol Rev."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Taccetti, G., Francalanci, M., Pizzamiglio, G., Messore, B., Carnovale, V., Cimino, G., and Cipolli, M. (2021). Cystic fibrosis: Recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10030338"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jcf.2016.09.002","article-title":"Continuous alternating inhaled antibiotic therapy in cf: A single center retrospective analysis","volume":"15","author":"Goeminne","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2014.11.005","article-title":"Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes","volume":"14","author":"Dasenbrook","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/03009734.2014.899279","article-title":"Combination antibiotic therapy for multidrug-resistant gram-negative bacteria","volume":"119","author":"Tangden","year":"2014","journal-title":"Ups. J. Med. Sci."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:29Z","timestamp":1760121869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["antibiotics12030484"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12030484","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}